



Coronavirus disease 2019 (COVID-19) is a highly 
communicable disease caused by severe acute respiratory 
syndrome coronavirus 2 (SARS‑CoV‑2), and the first case 
of the disease was reported in Wuhan, Peoples Republic 
of China (PRC), in December 2019.[1] Ninety-two million 
confirmed cases of COVID-19, with over 2.06 million 
COVID-19-associated deaths, had been reported globally as 
of January 23, 2021, and have led to enormous psychological, 
sociological, demographic, and economic crises around the 
world.[2,3] Far-reaching measures, such as extensive testing, 
nationwide lockdown, social distancing, and strict seclusion of 
infected persons, are necessary to prevent the further spread of 
SARS-CoV-2. However, employing these preventive measures 
geared toward containment is not a simple task to achieve.[4] 
This unremitting CoV spread underscores the significance 
of global efforts in developing vaccines and therapeutics. 
Furthermore, the return to normalcy appears to depend on the 
urgent rollout of an effective vaccine and rapid implementation 
of the vaccination.
Vaccines are biological agents that humanity usually count 
on to decrease the death tolls from infectious diseases and 
their agents. Within a year, immediately after the start of the 
COVID-19 pandemic, many teams of researchers domiciled 
in several countries took up the challenge of finding a lasting 
solution to the pandemic, and they came up with vaccines that 
can protect humans against SARS-CoV-2.[3] By January 2021, 
more than 290 candidate vaccines have been developed and 
tested; 69 candidate vaccines are currently in medical trials, 
including 43 in Phase one to three trials and 26 in Phase 
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two to three trials.[3,4] The speed at which these vaccines 
were developed was unprecedented in the history of vaccine 
development compared to other vaccines such as measles and 
typhoid, among others that took several years.[5,6] Furthermore, 
many countries where COVID-19 vaccination has commenced 
have executed phased distribution plans that prioritize those at 
high risk of exposure and transmission, including health-care 
workers and those at highest risk of complications and extreme 
adverse outcome, such as the elderly.[7] The expectation is 
that additional numbers of companies develop a vaccine for 
COVID-19, which can be made available for every nation of 
the world irrespective of their economic strength and race.
Before the COVID-19 pandemic, no available vaccine was 
shown to be potent against infection with any beta-CoV, the 
family that includes the SARS-CoV-2-aetiological agent 
causing COVID-19. The SARS caused by another beta-CoV 
ended on its own before considerably significant efforts at 
vaccine developments were commenced, and the fairly small 
number of the Middle East respiratory syndrome cases have not 
yet vindicated the huge‑scale financings and efforts required to 
determine whether preclinical vaccine entrants are effective.[8] 
As more efforts are being geared toward developing more 
effective vaccines with fewer side effects and increasing the 
supply of the existing ones to the middle-low-income countries 
who are not rich enough to afford these vaccines, it is hoped 
that there would be victory at last.
The article narratively reviewed original and review articles 
available on PubMed and Google Scholar databases.
types of coVId‑19 VaccInes
Whole‑virus vaccine
In general, whole-virus vaccines are derived from inactivated 
or live-attenuated viral particles, and this technology has been 
in use for decades. Live-attenuated vaccines are derived by 
passing disease-causing pathogens through cell culture in a 
foreign host to strip it of its pathogenic properties, so that it 
causes a mild infection that the recipient’s immune system can 
eliminate and subsequently develop a robust immunogenic 
response mechanism.[9] Three live-attenuated COVID-19 
vaccine candidates are currently in preclinical trials.[10]
Inactivated COVID-19 vaccines are made by growing the 
SARS-CoV-2 in Vero cell culture after that chemically 
inactivating the virus so that the viral particle loses its infectivity 
Table 2: Advantages and disadvantages of nucleic acid vaccines
Advantages Disadvantages
There is no live component, so no risk of the vaccine triggering the disease Some RNA vaccine requires ultra-cold storage
They are relatively easy to manufacture A booster shot may be required
The immune response involves B and T cells Has never been licensed in humans
Long-term persistence of DNA plasmids upon injection
DNA: Deoxyribonucleic acid, RNA: Ribonucleic acid
Table 1: Coronavirus disease‑2019 vaccine categories and important attributes
















Candidate vaccines. None approved yet
Nonreplicating
Johnson and Johnson’s (US) Johnson and Johnson’s (70%), two shots 2-8°C
Oxford AstraZeneca (UK) Oxford AstraZeneca (63% revised 73%), two shots Regular fridge temperature $4




Candidate vaccines. None approved yet
RNA
Moderna (US) Moderna (95%), two shots, 28 days apart −20°C $25






BBIBP-CorV: Beijing Institute of biological products corona vaccine, DNA: Deoxyribonucleic acid, RNA: Ribonucleic acid, CoronaVac: Coronavirus 
disease-2019 vaccine
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but can still trigger an immunogenic reaction in the recipient.[11] 
The Sinovac COVID-19 vaccine (CoronaVac) and Beijing 
Institute of Biological Products corona vaccine (BBIBP-CorV) 
developed by Chinese company Sinovac Biotech and Beijing 
Bio-Institute of Biological Products Co Ltd, respectively, 
are the two COVID-19 candidate vaccines created with the 
inactivated virus technology [Table 1].[9,12] These vaccines 
are injected into the body through the intramuscular route and 
contain adjuvants such as aluminum hydroxide that potentiate 
their immunogenic capacity. The immune response to these 
vaccines targets the envelope, spike, matrix, and nuclear 
proteins of SARS-COV-2 as the virus, as a whole, comes in 
contact with the recipient’s immune system.[10]
Randomized clinical trials for safety and efficacy demonstrated 
that CoronaVac was well tolerated and induced humoral 
responses against SARS-CoV-2. This influenced its 
endorsement for emergency use in PRC and ongoing Phase 
three clinical trials in three countries with a low dose of three 
microgram of CoronaVac in  3 and 6 µg  in 0.5ml volume of 
diluent confirmed on a day 0 and 14 vaccination schedule being 
studied in these trials.[12] The profile of safety of this novel 
vaccine was outstanding and comparable to that of the placebo. 
Overall, over 90% of recipients showed seroconversion.[10] The 
efficacy of this vaccine has yet to be established as the Phase 
three trials are still in progress at the time of this review.
The inactivated SARS-CoV-2 vaccine BBIBP-CorV clinical 
trial showed that it has a good safety profile, tolerability, and 
immunogenicity in apparently healthy people. Two-dose 
immunizations (with an interval of 28 days in-between 
the shots) at all doses (two microgram, four microgram, 
and eight microgram) in two age groups (>17 ≤59 years 
and >59 years) induced neutralizing antibodies in all of the 
vaccine recipients.[12] Recipients commonly develop mild 
adverse reactions in both vaccine trials, including pain and 
fever, and no serious vaccine-associated adverse events were 
reported in all groups.[13]
The inactivated COVID-19 vaccines use a killed form of the 
virus to trigger protective immunity to the organism in the 
recipient’s cells; therefore, it can protect humans without 
causing an infection. Thus, make it a choice in the vaccination 
of immunocompromised individuals. Inactivated vaccines 
are also considered more stable than live attenuated ones; 
hence, this type of COVID-19 vaccine potency will be better 
preserved. The challenges of the inactivated COVID-19 
vaccine, as with all other vaccines of this type, include 
induction of a weak or short-lived immune response that 
diminishes with time, hence the need for booster doses to 
evoke sufficient immune response.
Viral vector vaccine
A viral vector as a vaccine technology was initiated in the 
1970s. Besides been used as vaccines, it has also been used 
as gene therapy in cancer treatment.[14] Vaccinia virus, herpes 
virus, measles virus, adenovirus serotype five, and poxviruses 
have been developed as vectors for various vaccines whereby 
these viral vectors are stripped of replicating genes and diseases 
causing genes; genetic codes for the production of antigen from 
pathogen are attached into the vector genome.[14,15]
Viral vector vaccine uses a genetically modified form of a 
different virus (Vector) to deliver genetic materials for antigens 
into the human cells.[14] There are two types of viral vector 
vaccines – the replicating and the non-replicating vector 
vaccines.  The non-replicating vector vaccines produce the 
vaccine antigen when they infect human body cells but cannot 
retain the capacity to produce new viral particles. The replicating 
vector vaccines produce new viral particles (vaccine antigen) in 
the human cells they infect and then infect new human cells to 
develop new viral particles.[16] The vector is a different virus and 
harmless virus (it is not the virus that causes COVID-19), and 
this vector infects the human cells and transform into a piece 
of harmless virus (the spike protein (S) found on the surface 
of the virus that causes COVID-19) and make a considerable 
quantity of the antigen. The immunological system recognizes 
that the S protein on the COVID-19 virus’ surface as a foreign 
body then triggers the immune system to respond by producing 
antibodies and initiates the activation of other immune cells 
to fight the viral infection.[17] This helps develop a strong 
cellular immunological response by the T-lymphocytes and 
the production of the memory B-lymphocytes; this memory 
B-lymphocytes enable the human body to protect against 
future COVID-19 infection.[18] Some of the challenges of 
viral vector vaccines are that previous exposure to the virus 
vector may increase an immunological response against vector 
vaccine (antivector immunity) and reduce the effect of the 
vaccine.[19] Non-replicating viral vector vaccines are being 
authorized for use in the United States of America (USA).[18] 
An example is the Janssen COVID-19 Vaccine developed by 
Johnson and Johnson’s based in the USA.
Nucleic acid (deoxyribonucleic acid and ribonucleic acid)
Nucleic acid vaccine, a protein subunit, employs an 
antigen-encoding plasmid ribonucleic acid (RNA), messenger 
RNA (mRNA), viral replicons, or deoxyribonucleic acid (DNA) 
[Table 1]. The nucleic acid-encoded antigens can elicit both 
cell-mediated and humoral immunological responses upon 
their uptake and expression at the cellular level.[20] The 
production of antigens in the target cells has the benefit of 
mimicking protein production during infection.[20]
These DNA vaccines are produced by inserting an eukaryotic 
expression cassette encoding for the desired antigen (s) into a 
plasmid derived from bacteria.[20] DNA vaccines are usually 
injected intramuscularly. However, the problem is getting 
them to enter the human cell. This is a crucial step because the 
apparatus which allows the antigen to be translated into protein 
is situated within the cells. Different methods or technologies 
are being developed to support this process, such as (i) 
encapsulation of the DNA in nanoparticles which are devised 
to undergo fusion with the human cell membrane; (ii) the use 
of “gene gun,” which makes use of helium to propel DNA into 
skin cells; and (iii) the use of electroporation method, where 
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short pulses of electrical current are used to generate temporary 
pores in membranes of human cells.[20]
RNA vaccines encode the desired antigen in mRNA or 
self-amplifying RNA, which are molecular templates used by 
cellular factories to make proteins. Because of its transitory 
nature, there is virtually no risk of it getting incorporated into 
human genetic material. Instead, the RNA particle can be injected 
by itself, encapsulated within nanoparticles (as in Pfizer’s 
mRNA-based COVID-19 vaccine), or driven into cells using 
some of the similar methods being devised for DNA vaccines.
Once the RNA or DNA particle is in the cell and commences 
antigens production, these are then manifest on its surface, 
where they can be identified by the immunological system 
and trigger a response. This response includes killer 
T-lymphocytes that search for infected cells to destroy 
such cells, antibody-producing B-lymphocytes, and helper 
T-lymphocytes that aid the production of antibodies. Once 
introduced into the host cell, the genetic material is read 
by the cell’s protein and used to produce an antigen, which 
then triggers an immunological response. This technology 
is relatively recent, although RNA and DNA vaccines 
are being developed against diseases such as the human 
immunodeficiency virus, Zika virus, and now COVID‑19. So 
far, none has been licensed yet for use in humans. However, 
many DNA vaccines are licensed for animal use, such as an 
equine vaccine against West Nile Virus. The advantages and 
disadvantages of nucleic acid vaccines  are in Table 2.
Protein subunit vaccine
Subunit vaccines contain a specific part of a pathogen that acts 
as antigens, eliciting an immune response from the host. They 
do not contain any genetic material nor live components of the 
organism: they contain only the antigens capable of causing 
an immune response.[21] These types of subunit vaccines are 
grouped protein subunit vaccines, polysaccharide vaccines, 
and conjugate subunit vaccines.
The protein subunit vaccines contain specific isolated antigen 
fragments, usually from membrane proteins of pathologic 
organisms that best stimulate the immune response in the 
host.[21] Like other types of subunit vaccines, they do not 
contain viral genetic material and cannot infect or replicate 
within the host. These proteins, once identified, can be 
synthesised or produced by recombinant techniques and 
packaged into vaccines that can be administered.[18,21,22]
The persistence of neutralising antibodies and memory of 
the immune system against these antigens offer long term 
protection by preventing the attachment of this viral particle 
to the host cells when encountered. The receptor-binding 
domain within the spike (S) protein of SARS-CoV-2 is the most 
appropriate antigen to stimulate the neutralising antibodies to 
inhibit COVID-19 infection.[18]
The benefits of the protein subunit vaccines (i) are that they 
are safe since they do not carry any genetic material, thus 
no risk of replicating within the host, therefore unable to 
cause infection in recipients.[18,23] (ii) they are stable product 
and do not require storage in very low-temperature freezers 
to preserve their potency as required by other vaccines like 
the whole virus or live attenuated vaccines.[23] (iii) It can be 
given to individuals with weakened immune systems due to 
its inability to replicate or transform to a live form[23] and (iv) 
there are minimal adverse reactions due to the use of only the 
specific antigens that best evoke an immune response for the 
production of the vaccine, and other antigens that increase the 
risk of adverse reactions are not present.[18,23]
The disadvantages of protein subunit vaccine are (i) there is 
the risk of generating weak immune responses due to several 
factors such as the exclusion of other antigens other than the 
main ones that trigger the immune response, also means the 
pathogen-associated molecular patterns which contribute to 
immune response would be excluded[23] and (ii) they have 
minimal or suboptimal cell-mediated immunity if any,[8] (iii) the 
production is more complex and more time consuming as the 
various antigens of the virus has to be examined to determine 
which ones would be included in the vaccine,[18,23] (iv) It is 
also more expensive to manufacture,[23] and (v) The long term 
protection offered by immune memory is not sacrosanct.[18]
The use of adjuncts which are agents that stimulate and/or 
prolong immune response, and booster doses, which lead to 
repeated sensitisation and increased immune response, are 
used to overcome this shortfall of minimal or suboptimal 
cell-mediated immunity.[18]
Only one protein subunit vaccine (EpiVacCorona) has been 
approved for vaccination in the human population (only in 
Russia); however, several vaccine candidates are at different 
phases of clinical and preclinical trials.[22,24]
Myths around coVId‑19 VaccInes
Myths are stories in the category of folklore, often endorsed in 
society, traditionally or religiously, and which shape the beliefs 
and daily lives and attitudes of humans.[25] In the history of 
man and diseases, there have been several myths, including 
leprosy and tuberculosis, as well as with vaccines, for instance, 
the flu vaccine or measle depending on the time or territory. 
At present, the novel CoV pandemic has necessitated the 
institution of control and preventive measures and research into 
vaccination to hinder the spread of the virus among humans 
and build herd immunity in populations. However, despite 
the massive awareness efforts to the public on the COVID‑19 
vaccines, serious criticisms with many myths and conspiracies 
discouraging its use have arisen among individuals and 
societies, which has spread quickly in this age of digital and 
social media, including WhatsApp, Facebook, Twitter leading 
to a “disinfodemic.”[25,26]
The prevailing myths surrounding COVID-19 vaccines, which 
though false, are generating anxiety about their uptake, include: 
“COVID‑19 vaccines can give me the disease;” “I will test 
positive for COVID‑19 after the vaccination;” “I have already 
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had and recovered from COVID, I do not need the vaccine;” 
“My DNA will be changed by the COVID‑19 vaccine”[27,28] 
Indeed, many Nigerians still fundamentally hold beliefs 
suggesting the disease cannot thrive/are easily destroyed in 
the country such as: “It is a disease of white people;” “The 
virus cannot thrive the very hot weather in Nigeria;” “Hot 
drinks/local gins destroy CoV,” and such extreme myth as 
“COVID‑19 is not real.”[29] These myths further propagate the 
basis for non-belief in the need for a vaccine and further create 
challenges for COVID-19 vaccine uptake.
The dangers in the belief and adoption of these myths and 
conspiracy theories are that such individuals are more likely to 
share and spread these myths; they connect to other forms of 
distrust, exhibit low compliance with governmental guidelines, 
and show increased hesitancy towards the uptake of vaccines.[30] 
Thus, there is a need for in-depth study of the prevailing myths 
and conspiracy theories to address them to pave the way for 
improved acceptance and uptake of the COVID-19 vaccines. 
Finally, it is worth emphasising as a deterrent to the vaccine 
theorists that such myths are detrimental to societies and can 
be punishable through cyber policing.[31]
adVerse eVents followIng IMMunIsatIon wIth 
coVId‑19 VaccIne
According to the World Health Organization (WHO), the term 
“adverse event following immunisation” (AEFI) is referred 
to as “any untoward medical occurrence which follows 
immunisation and which does not necessarily have a causal 
relationship with the usage of the vaccine.”[32,33] Furthermore, 
this event can be an anomalous lab finding, an unfavourable 
or unintended sign, a symptom, or a disease.[32]
Based on severity, AEFIs can be classified into minor or 
serious.[34] The minor AEFIs are common events, and they 
pose no potential health risk to the receiver of a vaccine 
dose;[3,4] they include rash, fever, malaise, loss of appetite, 
reactions at the injection site (such as redness, tenderness and 
swelling), and other mild reactions.[34,35] The serious AEFIs 
are rare events. An AEFI is considered a serious AEFI if it 
is life-threatening or results in hospitalisation, persistent or 
major disability/incapacity, birth defect (if the receiver of the 
vaccine dose is a pregnant woman), or death of the vaccine 
dose receiver.[34,35]
All vaccines, when received, have the potential to cause an 
AEFI.[32-35] The level of severity (minor or severe) of AEFIs 
associated with a vaccine, as well as the frequency of the AEFIs 
observed with such a vaccine, is one of the major determinants 
used in assessing the safety profile of the vaccine.[36,37] Before 
a vaccine can be certified to be safe by the vaccine regulatory 
body/agency of a nation, it must have satisfactory reports on 
AEFI at the preclinical and clinical phases of its development. 
Postcertification, AEFI data collection, analysis and monitoring 
also continue from the day its use begins in the general 
population.[38]
Traditionally, it takes many years to develop a vaccine. 
However, the COVID-19 vaccine development timeline was 
an exception; the period spent in the trial of the COVID-19 
vaccine was quite very short due to the urgent need for the 
vaccine globally.[38] As a result, the AEFIs associated with the 
vaccine may still not be fully known and deeply studied to a 
conclusive point. Available data has shown that AEFIs occurred 
in 0.015% of the COVID-19 vaccine doses administered, of 
which two-thirds of these AEFIs were minor ones.[39] Incidence 
of (0.03%) adverse events after receipt of Moderna COVID-19 
vaccine were submitted to Vaccine Adverse Event Reporting 
System.[40]
Close surveillance of COVID-19 vaccine-related AEFIs during 
the rollout of the vaccine for use in the general population needs 
to be taken very seriously. The surveillance of this vaccine’s 
AEFIs will help understand the vaccine deeper, guide public 
health laws, policies, and strategies regarding COVID-19 
vaccination; in preparation for public health emergencies, and 
build public trust about the vaccine.[41]
conclusIon
Pandemics have raised the awareness of global threats caused 
by newly emerging pathogens and has provided the motivation 
to prepare against future pandemics through the development 
of new vaccines to provide viable solutions. Some have 
demonstrated a high level of effectiveness with the use of 
adjuncts with good safety profiles. The COVID‑19 vaccine 
distribution to every part of the world is being worked towards 
by many health agencies in the world, especially WHO, 
UNICEF and other partners, and every head of state should 
continue to sensitise its people on the vaccine, its importance 
and the need to take it once it is made available. According to 
the WHO, the COVID-19 vaccine goal is for it to be a global 
public good, although it is also important to note that taking 
the vaccine should not stop essential public actions such as 
physical distancing, use of face masks, and sanitisation of 
hands to reduce the rate of transmission and subsequently 
reduce mortality.
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